The pain killer Almotriptan and registered under the following trade names in the respective countries, Almotriptan Axert ® USA-Canada, Almogran ® Belgium, Denmark, Finland, Germany, Italy, Ireland, Portugal, Spain, United Kingdom, Netherlands, Sweden, Switzerland, South Korea and as Almotrex ® Italy and Amignul ® Spain.
The antimigraine drug almotriptan eas researched and produced by the Laboratorios of Almirall, is available in 12.5 mg in most countries and at 6.25 mg in the U.S. and Canada.
It was the first drug developed and produced by a Spanish laboratory to be approved by the Food and Drug Administration, its acronym being the FDA, for marketing in the United States.
Almotriptan is prescribed to treat the acute headache phase of a migraine attack, and almotriptan is the only oral triptan approved in the U.S. for the treatment of migraine in adolescents between the ages of 12 to 17.
Mode of action
Almotriptan is a potent and selective serotonin agonist, 5-HT1B/1D, that due to the particular distribution of the receptors of the 5-HT1B/1D, almotriptan basically shrinks the human meningeal arteries, resulting in a limited effect on the arteries that supply blood to the brain, yet having little effect on heart and lung vessels.
Almotriptan has no relevant pharmacokinetic interactions and is metabolized by different pathways, and does not require dosage adjustment in patients with mild kidney or liver failure. There are also no observable clinical differences between men, women, young and old.
The effectiveness of Almotriptan in the treatment of acute migraine attack is established in clinical studies of 3,000 patients, who were given the 12.5 mg dose and showed that the drug had a rapid and highly effective effect of relieving the pain. Almotriptan relieves nausea, vomiting photophobia, hypersensitivity to light and phonophobia, hypersensitivity to sound, associated with migraine attacks.
In the “Act when Mild ‘ recent study, a program that takes action in the early stages of the onset of a migraine attack, has shown that taking Almotriptan at the first signs of the migraine attack, when pain is still mild, provides the best results in minimizing pain associated with these migraine attacks.
Hypersensitivity to active substance or any of its excipients, as in the case of other receptor agonists 5HT1B/1D, Almotriptan should not be used in patients with a history, or who have symptoms or signs of ischemic heart disease, myocardial infarction, angina pectoris, documented silent ischemia, angina Prinzmetal or severe hypertension and hypertension mild or moderate uncontrolled.
Patients with previous cerebrovascular accidents CVA or transient ischemic attacks TIAs,
Peripheral vascular disease. They are contraindicated that the concomitant administration with ergotamine, ergot derivatives, including metisargida and other agonists 5-HT1B/1D.
Patients with severe liver failure.
Almotriptan has been shown to have an adverse effect profile, similar to the use of a placebo, when used as directed in line with the product characteristics.